Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LG Life Obtains Korea FDA Approval To Conduct Clinical Trials For Biosimilar Following Celltrion, Hanwha

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's LG Life Sciences became the third local pharma company to obtain Korea FDA approval to conduct clinical trials of its biosimilar, code-named LBEC0101, on the heels of clinical trial clearance for Celltrion and Hanwha Chemicals

You may also be interested in...

Samsung Bioepis Files Biosimilar Enbrel In South Korea

Samsung Bioepis has applied for the approval in South Korea of production and sales of SB4, its biosimilar version of Amgen Inc.’s arthritis blockbuster Enbrel (etanercept).

Korean Companies Step Up Development Of Enbrel Biosimilars As Amgen Ramps Up Its Pipeline

After halting trials of its Rituxan biosimilar last year, Samsung Bioepis is focusing on its Enbrel biosimilar and has begun Phase I trials. Other Korean pharma are developing biosimilars of Enbrel, with Hanwha expecting approval in Korea this year.

Korea Biosimilar Play LG Life Sciences Names New CEO Amid Unfriendly Business Conditions

SEOUL - LG Life Sciences has reshuffled its top management and named Jung Il-Jae as new CEO and President. Kim In-Chull had served as president of LG Life Sciences since 2006, and took the lead in aggressively moving the company into the biosimilar space. The company said only that Kim will now serve as an advisor to the company

Related Content

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts